PE15412018A1 - Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug - Google Patents

Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug

Info

Publication number
PE15412018A1
PE15412018A1 PE2018001272A PE0012722018A PE15412018A1 PE 15412018 A1 PE15412018 A1 PE 15412018A1 PE 2018001272 A PE2018001272 A PE 2018001272A PE 0012722018 A PE0012722018 A PE 0012722018A PE 15412018 A1 PE15412018 A1 PE 15412018A1
Authority
PE
Peru
Prior art keywords
amino acids
appls
compounds
terminal capable
functionalized derivatives
Prior art date
Application number
PE2018001272A
Other languages
Spanish (es)
Inventor
Yizhou Dong
Kevin Thomas Love
Robert S Langer
Daniel Griffith Anderson
Delai Chen
Yi Chen
Arturo Jose Vegas
Akinleye Alabi
Yunlong Zhang
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161552423P priority Critical
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of PE15412018A1 publication Critical patent/PE15412018A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2121/00Preparations for use in therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/463The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]

Abstract

Se refiere a compuestos APPLs y composiciones que se caracterizan por las formulas Markush (I), (II), (III), (IV), (V) y (VI), en donde al menos un grupo amino terminal esta adicionalmente funcionalizado al tener un grupo del tipo (i), (ii) o (iii), dichos compuestos se obtienen haciendo reaccionar un grupo amino terminal o interno con epoxidos, acrilatos o aldehidos que tienen grupos lipofilicos; compounds APPLS and compositions characterized by the Markush formulas (I), (II), (III), (IV), (V) and (VI), wherein at least one terminal amino group is referred additionally functionalized to having a group of type (i), (ii) or (iii), said compounds are obtained by reacting a terminal or internal amino group with epoxides, acrylates or aldehydes having lipophilic groups; los aminoacidos, peptidos, polipeptido-lipidos resultantes (llamados "APPLs"). amino acids, peptides, polypeptide-lipid resulting (called "APPLS"). Los compuestos APPLs son utiles en terapia de genes como la capacidad de unirse a polinucleotidos, bioprocesamiento o la administracion y/o suministro de un agente terapeutico, entre otros. The APPLS compounds are useful in gene therapy as the ability to bind polynucleotides, bioprocessing or administration and / or delivery of a therapeutic agent, among others.
PE2018001272A 2011-10-27 2012-10-26 Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug PE15412018A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201161552423P true 2011-10-27 2011-10-27

Publications (1)

Publication Number Publication Date
PE15412018A1 true PE15412018A1 (en) 2018-09-26

Family

ID=47146733

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018001272A PE15412018A1 (en) 2011-10-27 2012-10-26 Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug
PE2014000601A PE00412015A1 (en) 2011-10-27 2012-10-26 Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000601A PE00412015A1 (en) 2011-10-27 2012-10-26 Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug

Country Status (17)

Country Link
US (3) US9512073B2 (en)
EP (1) EP2771319A1 (en)
JP (2) JP6151707B2 (en)
KR (1) KR20150000461A (en)
CN (2) CN104136419B (en)
AU (2) AU2012328570B2 (en)
BR (1) BR112014010050A8 (en)
CA (1) CA2853522A1 (en)
CL (1) CL2014001070A1 (en)
EA (1) EA201490847A1 (en)
HK (1) HK1201525A1 (en)
IL (3) IL232158D0 (en)
MX (1) MX2014005072A (en)
NZ (2) NZ624223A (en)
PE (2) PE15412018A1 (en)
SG (1) SG11201401885TA (en)
WO (1) WO2013063468A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004203682B2 (en) 2003-01-06 2009-10-01 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP1912679A4 (en) * 2005-06-15 2009-07-29 Massachusetts Inst Technology Amine-containing lipids and uses thereof
WO2009127072A1 (en) 2008-04-18 2009-10-22 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
JP5705118B2 (en) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド Etoposide and doxorubicin conjugates for drug delivery
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
CA2745524A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CN102300987A (en) 2008-12-17 2011-12-28 安吉奥开米公司 -1 membrane type matrix metalloproteinase inhibitors and their use
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc Multimeric peptide conjugates and uses thereof
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2857413A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140044356A (en) 2011-06-08 2014-04-14 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
PE15412018A1 (en) 2011-10-27 2018-09-26 Massachusetts Inst Technology Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
AU2014239184B2 (en) 2013-03-14 2018-11-08 Translate Bio, Inc. Methods and compositions for delivering mRNA coded antibodies
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
DK2968586T3 (en) 2013-03-14 2018-10-08 Translate Bio Inc CFTR mRNA compositions and related methods and uses
MX2015012865A (en) 2013-03-14 2016-07-21 Shire Human Genetic Therapies Methods for purification of messenger rna.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2014340092A1 (en) * 2013-10-22 2016-05-05 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
EA201690581A1 (en) * 2013-10-22 2016-09-30 Шир Хьюман Дженетик Терапис, Инк. TREATMENT OF phenylketonuria C mRNA
JP2016535738A (en) 2013-10-22 2016-11-17 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Lipid formulations for the delivery of messenger rna
CN105658800A (en) * 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 CNS delivery of MRNA and uses thereof
MX2016011686A (en) 2014-03-09 2016-11-07 Univ Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency.
JP6372118B2 (en) * 2014-03-18 2018-08-15 東洋インキScホールディングス株式会社 Method and manufacturing amphoteric surfactants
US20170143848A1 (en) 2014-03-24 2017-05-25 Shire Human Genetic Therapies, Inc. Mrna therapy for the treatment of ocular diseases
CA2944800A1 (en) 2014-04-25 2015-10-29 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) * 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
WO2015191693A2 (en) * 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
CN106795142A (en) * 2014-06-24 2017-05-31 夏尔人类遗传性治疗公司 Stereochemically enriched compositions for delivery of nucleic acids
AU2015283954A1 (en) 2014-07-02 2016-12-22 Translate Bio, Inc. Encapsulation of messenger RNA
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016025643A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Brush-poly(glycoamidoamine)-lipids and uses thereof
EP3226912A1 (en) 2014-12-05 2017-10-11 Rana Therapeutics Inc. Messenger rna therapy for treatment of articular disease
US20180147166A1 (en) * 2015-05-21 2018-05-31 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3394093A1 (en) 2015-12-23 2018-10-31 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
CA3027312A1 (en) 2016-06-13 2017-12-21 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
WO2018089846A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Subcutaneous delivery of messenger rna
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
US20180251755A1 (en) 2017-02-27 2018-09-06 Translate Bio, Inc. Methods For Purification of Messenger RNA
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
WO2018165257A1 (en) 2017-03-07 2018-09-13 Translate Bio, Inc. Polyanionic delivery of nucleic acids
US20180333457A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR
WO2018236849A1 (en) 2017-06-19 2018-12-27 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
EP3461487A1 (en) * 2017-09-29 2019-04-03 Nlife Therapeutics S.L. Compositions and methods for the delivery of mrna to hepatic cells

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844629A (en) 1956-04-25 1958-07-22 American Home Prod Fatty acid amides and derivatives thereof
US4022833A (en) 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
JPS49127908A (en) 1973-04-20 1974-12-07
JPS5123537A (en) 1974-04-26 1976-02-25 Adeka Argus Chemical Co Ltd Kasozaisoseibutsu
JPS5813576B2 (en) 1974-12-27 1983-03-14 Adeka Argus Chemical Co Ltd
DE2520814A1 (en) 1975-05-09 1976-11-18 Bayer Ag Light stabilisation of polyurethanes - using polymeric tert. amines from aliphatic diamines and (meth)acrylic esters or amides
US4265745A (en) 1977-05-25 1981-05-05 Teijin Limited Permselective membrane
US4308085A (en) 1980-07-28 1981-12-29 Jenoptik Jena Gmbh Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
CA1320724C (en) 1985-07-19 1993-07-27 Koichi Kanehira Terpene amino alcohols and medicinal uses thereof
EP0211305B1 (en) 1985-08-05 1992-07-01 Miyoshi Yushi Kabushiki Kaisha Metal scavenging process
DE3616824A1 (en) 1986-05-17 1987-11-19 Schering Ag printing inks use of curable resin blends for oberflaechenbeschichtungen and and process for their manufacture
US4873370A (en) 1987-03-03 1989-10-10 Pennzoil Products Company Alkylene diamines for use in friction and wear reducing compositions
FR2645866B1 (en) 1989-04-17 1991-07-05 Centre Nat Rech Scient News lipopolyamines, their preparation and their use
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5380778A (en) 1992-09-30 1995-01-10 Minnesota Mining And Manufacturing Company Fluorochemical aminoalcohols
JPH06211978A (en) 1992-10-28 1994-08-02 Takeda Chem Ind Ltd New polyether polyol and production of polyurethane foam therefrom
JP3189279B2 (en) 1993-02-19 2001-07-16 日本新薬株式会社 Nucleic acid copolymers containing pharmaceutical compositions
AU677144B2 (en) 1993-11-24 1997-04-10 Valentis, Inc. Amphiphilic derivatives of piperazine
US5464924A (en) 1994-01-07 1995-11-07 The Dow Chemical Company Flexible poly(amino ethers) for barrier packaging
US5624976A (en) 1994-03-25 1997-04-29 Dentsply Gmbh Dental filling composition and method
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
JPH10197978A (en) 1997-01-09 1998-07-31 Mitsubishi Paper Mills Ltd Silver halide photographic sensitive material
JPH115786A (en) 1997-06-13 1999-01-12 Pola Chem Ind Inc Novel aminohydroxypropylpiperazine derivative
JPH1180142A (en) 1997-09-05 1999-03-26 Pola Chem Ind Inc Production of diphenylalkyl compound
FR2774092B1 (en) 1998-01-26 2000-02-18 Air Liquide A process for preparing polyazacycloalkanes silica gel grafts and grafts using compounds
DE19822602A1 (en) 1998-05-20 1999-11-25 Goldschmidt Ag Th A process for preparing Polyaminosäureestern by esterification of acidic polyamino acids or transesterification of Polyaminosäureestern
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
DK1808438T3 (en) 1999-06-29 2014-10-27 Mannkind Corp Purification and stabilization of peptide and protein drugs in
DE19937721A1 (en) 1999-08-10 2001-02-15 Max Planck Gesellschaft new diketopiperazine
CA2395636A1 (en) 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
IL138474D0 (en) 2000-09-14 2001-10-31 Epox Ltd Highly branched water-soluble polyamine oligomers, process for their preparation and applications thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6656977B2 (en) 2001-07-20 2003-12-02 Air Products And Chemical, Inc. Alkyl glycidyl ether-capped polyamine foam control agents
US7601367B2 (en) 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
AU2002347035B2 (en) 2001-09-28 2008-04-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Micro-RNA molecules
DE10207178A1 (en) 2002-02-19 2003-09-04 Novosom Ag Components for the preparation of amphoteric liposomes
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
JP2006505644A (en) 2002-11-04 2006-02-16 ジーイー・バイエル・シリコーンズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツトゲゼルシヤフト Linear polyamino and / or polyammonium polysiloxane copolymer i
CA2506843A1 (en) * 2002-11-22 2004-06-10 Novo-Nordisk A/S 2,5-diketopiperazines for the treatment of obesity
US6998508B2 (en) 2003-03-10 2006-02-14 Air Products And Chemicals, Inc. Tertiary alkanolamines containing surface active alkyl groups
WO2005007810A2 (en) 2003-06-16 2005-01-27 Grinstaff Mark W Functional synthetic molecules and macromolecules for gene delivery
US20050123596A1 (en) 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
ES2547220T3 (en) 2004-04-20 2015-10-02 Dendritic Nanotechnologies, Inc. Dendritic polymers with improved amplification and interior functionality
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
DE102004043342A1 (en) 2004-09-08 2006-03-09 Bayer Materialscience Ag Blocked polyurethane prepolymers as adhesives
GB0502482D0 (en) 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
EP1869106B1 (en) 2005-03-28 2014-06-25 Dendritic Nanotechnologies, Inc. Janus dendrimers and dendrons
EP1912679A4 (en) 2005-06-15 2009-07-29 Massachusetts Inst Technology Amine-containing lipids and uses thereof
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007073489A2 (en) 2005-12-22 2007-06-28 Trustees Of Boston University Molecules for gene delivery and gene therapy, and methods of use thereof
CN100569877C (en) 2005-12-30 2009-12-16 财团法人工业技术研究院;新力美科技股份有限公司 Branched structure compound containing UV crosslinking reactive group and application thereof
JP5599975B2 (en) 2006-02-22 2014-10-01 マンカインド コーポレイション Method for improving the formulation properties of the fine particles containing diketopiperazine and an active agent
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
US20070275923A1 (en) 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
EP2032652A4 (en) 2006-06-05 2011-08-17 Massachusetts Inst Technology Crosslinked, degradable polymers and uses thereof
ES2293834B1 (en) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compound with inhibitory activity of UBC13-UEV interactions, pharmaceutical compositions comprising it and its therapeutic applications.
US8071082B2 (en) 2006-07-21 2011-12-06 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
EP2139461A2 (en) 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
JP5186126B2 (en) 2007-03-29 2013-04-17 公益財団法人地球環境産業技術研究機構 New triazine derivatives and use as their preparation and their gas separation membrane
WO2008137470A1 (en) 2007-05-01 2008-11-13 Pgr-Solutions Multi-chain lipophilic polyamines
GB0716897D0 (en) * 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
CN104672311A (en) 2007-10-02 2015-06-03 玛瑞纳生物技术有限公司 Lipopeptides for delivery of nucleic acids
WO2009086547A1 (en) 2008-01-03 2009-07-09 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
CA2984026A1 (en) 2008-10-09 2010-04-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP2902013A1 (en) 2008-10-16 2015-08-05 Marina Biotech, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
WO2010062322A2 (en) 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
JP5788806B2 (en) * 2008-12-29 2015-10-07 マンカインド コーポレイション Drug delivery agent for a substituted diketopiperazine and its salts, therapeutic compositions containing them, particulate compositions and dry powder composition, as well as the adjustment method
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US20100222489A1 (en) 2009-02-27 2010-09-02 Jiang Dayue D Copolymer composition, membrane article, and methods thereof
CN102334237B (en) * 2009-04-02 2015-05-13 西蒙公司 Telecommunications patch panel
JP5769701B2 (en) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation Lipid composition
WO2010132876A1 (en) 2009-05-15 2010-11-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Polymers for delivering a substance into a cell
BRPI1013154A2 (en) * 2009-06-12 2016-04-05 Mannkind Corp microparticles of diketopiperazine with specific surface areas defined.
MX2012001339A (en) * 2009-07-30 2012-03-07 Salvat Lab Sa Apaf-1 inhibitor compounds.
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
CN101863544B (en) 2010-06-29 2011-09-28 湖南科技大学 Cyanuric acid-based heavy metal chelating flocculant and preparation method thereof
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012133737A1 (en) 2011-03-31 2012-10-04 公益財団法人地球環境産業技術研究機構 Crosslinkable amine compound, polymer membrane using crosslinkable amine compound, and method for producing polymer membrane
EP2532649B1 (en) 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
CN103748078B (en) 2011-06-08 2016-11-09 夏尔人类遗传性治疗公司 Cleavable lipid
KR20140044356A (en) 2011-06-08 2014-04-14 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
PE15412018A1 (en) 2011-10-27 2018-09-26 Massachusetts Inst Technology Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
JP5991937B2 (en) 2013-03-06 2016-09-14 Jxエネルギー株式会社 Friction modifiers and lubricating oil compositions
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9895443B2 (en) 2013-06-26 2018-02-20 Massachusetts Institute Of Technology Multi-tailed lipids and uses thereof
KR101355583B1 (en) 2013-10-04 2014-01-24 한국지질자원연구원 Simplicity valuable mineral decollator and valuable mineral separating method using thereof
JP2016535738A (en) 2013-10-22 2016-11-17 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Lipid formulations for the delivery of messenger rna
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell

Also Published As

Publication number Publication date
MX2014005072A (en) 2014-07-28
EP2771319A1 (en) 2014-09-03
IL259414D0 (en) 2018-07-31
KR20150000461A (en) 2015-01-02
WO2013063468A8 (en) 2014-03-06
JP6151707B2 (en) 2017-06-21
US20180036333A9 (en) 2018-02-08
AU2012328570A1 (en) 2014-05-22
AU2012328570B2 (en) 2017-08-31
NZ624223A (en) 2016-06-24
US9512073B2 (en) 2016-12-06
WO2013063468A1 (en) 2013-05-02
BR112014010050A8 (en) 2017-06-20
SG11201401885TA (en) 2014-09-26
US10086013B2 (en) 2018-10-02
US20190076462A1 (en) 2019-03-14
US20130158021A1 (en) 2013-06-20
JP2017222642A (en) 2017-12-21
PE00412015A1 (en) 2015-01-28
HK1201525A1 (en) 2015-09-04
IL232158D0 (en) 2014-05-28
IL250740D0 (en) 2017-04-30
CN107522664A (en) 2017-12-29
JP2014534220A (en) 2014-12-18
BR112014010050A2 (en) 2017-06-13
CN104136419A (en) 2014-11-05
US20170165290A1 (en) 2017-06-15
CN104136419B (en) 2017-11-03
EA201490847A1 (en) 2014-12-30
NZ719941A (en) 2017-11-24
CL2014001070A1 (en) 2014-11-21
IL250740A (en) 2018-06-28
CA2853522A1 (en) 2013-05-02
AU2017265103A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
CY1116942T1 (en) Anti-iikes COMPOUNDS
CY1117580T1 (en) New heterocyclic derivatives and their use in treating neurological disorders
ECSP12012067A (en) Inhibitors of Hepatitis C virus
DOP2012000225A (en) Pyrrolo-pyrimidine as inhibitors of CDK4 / 6
EA201101618A1 (en) Arylpyridines as aldosterone synthase inhibitors
EA201290089A1 (en) Chemical compounds
EA201270467A1 (en) Polycyclic compounds as antagonists of the lysophosphatidic acid receptors
EA201101507A1 (en) Methods for treating solid tumors
GT201400164A (en) Compounds imidazopirrolidinona
EA201391670A1 (en) 1,3-oxazines as bace1 inhibitors and / or bace2
CU20110129A7 (en) Pyridyloxy-indoles of VEGF-R2 inhibitors and use thereof for treating diseases
CR20110679A (en) subcutaneous formulation of anti-her2
BR112015014714B1 (en) carbamoilpiridona polycyclic compounds, the pharmaceutical composition comprises and their pharmaceutical use
EA201591244A1 (en) antiviral compounds
CO6541656A2 (en) 2-amino-5.5- difluoro-5,6-dihydro-4h-oxazines as BACE1 inhibitors and / or BACE 2
AR084237A1 (en) Methods to treat hepatitis C (HCV), composition
CL2017001769A1 (en) Compounds derived from nucleosides, nucleotides and analogues thereof; pharmaceutical composition comprising; useful in the treatment of hepatitis c (divisional of application 1699-2015).
CY1113299T1 (en) Aprotininis polypeptides for transporting A COMPOUND within the BBB
CY1115836T1 (en) Pyrazinonis derivatives and their use in the treatment of lung diseases
PE00412015A1 (en) Functionalized derivatives of amino acids in the n terminal capable of forming microspheres encapsulating drug
ECSP12012065A (en) Pyrazine derivatives and their use in treating neurological disorders
UY33445A (en) A dosing regimen, methods for treating Hepatitis C virus, pharmaceutical composition comprising anti-HCV compounds and kit
CR20120237A (en) Derivatives carbamoyl-methyl-amino-substituted acetic acid as NEP inhibitors novel
BR112013028430A2 (en) compound, pharmaceutical composition, method of treating a disease or condition mediated by spleen tyrosine kinase (Syk), and use of a therapeutically effective amount of the compound
CY1116075T1 (en) NEW COMPOSITIONS liposomes